A Study To Monitor Long-Term Treatment With PF-00547659

• Status: Completed
• Trial end date: 2016-07-27
• Target enrollment: 0
• Participant gender: All

Summary

This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Shire

Criteria

Inclusion Criteria:

• Subjects between 18 and 76 years of age.

• Subjects previously enrolled in study A7281006 who have completed the blinded 84 day (12 week) induction period or in study A7281008 who have completed Week 12 and have demonstrated a clinical response as defined by that protocol.

Exclusion Criteria:

• Subjects that have completed Day 84 (Week 12) of a PF-00547659 study but have experienced serious event(s) related to the investigational product, an unstable medical condition, or any other reason, in the opinion of the investigator, would hinder entry or participation in this study.

• Subjects who are taking any dose of azathioprine, 6-mercaptopurine or methotrexate.